Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation.
Bruins Slot KM
, Berge E
Department of Internal Medicine, Oslo University Hospital, Oslo, Norway, NO-0407.
Full Text Sources
Other Literature Sources
Anticoagulant treatment with vitamin K antagonists (VKAs) is aimed at preventing thromboembolic complications and has been the therapy of choice for most people with non-valvular atrial fibrillation (AF) for many decades. A new class of anticoagulants, the factor Xa inhibitors, appear to have several pharmacological and practical advantages over VKAs.
PMID: 23925867 [PubMed - as supplied by publisher]